Dr Frost was “unanimously voted” by the Board to continue in the position he has held since March 2010.
Professor Moshe Many, Teva’s Vice Chairman of the Board, said Dr Frost has the leadership committees’ “full support”.
The former Chief Executive Officer and President of IVAX Corporation – which Teva acquired in 2006 – previously served as Vice Chairman before taking on the role of chair two years ago.
“We will continue to benefit from his vision and guidance,” Professor Many commented. “We look forward to the progress of the Company under the governance of the Board and the leadership of Teva’s President and CEO Dr Jeremy Levin.”
Headquartered in Israel, Teva is the largest generic manufacturer in the world with a global portfolio of more than 1,300 molecules and a direct presence in around 60 countries.